We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Hypokalemia after rituximab administration in nephrotic syndrome: two case reports.
- Authors
Song, Yiyun; Ding, Lin; An, Xin; Zhao, Yi; Li, Xianhua; Yang, Xiangdong; Xiao, Xiaoyan
- Abstract
Rituximab, a chimeric anti-CD20 monoclonal antibody, is an effective treatment for nephrotic syndrome. Hypokalemia is a rare adverse reaction among patients treated with rituximab although there have been extensive reports of acute and chronic adverse events with the administration of rituximab. We herein report two cases of symptomatic hypokalemia after intravenous rituximab administration in our center, to help health professionals consider the possibility of acute hypokalemia after rituximab administration, monitor potassium timely and develop an appropriate treatment plan.
- Subjects
NEPHROTIC syndrome; RITUXIMAB; HYPOKALEMIA; MEDICAL personnel; MONOCLONAL antibodies; INTRAVENOUS therapy
- Publication
BMC Nephrology, 2023, Vol 24, Issue 1, p1
- ISSN
1471-2369
- Publication type
Article
- DOI
10.1186/s12882-023-03079-4